<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03896477</url>
  </required_header>
  <id_info>
    <org_study_id>CVIA-074</org_study_id>
    <nct_id>NCT03896477</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) Administered in a 2+1 Schedule to Healthy Infants</brief_title>
  <official_title>A Phase 3, Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's 10-Valent Pneumococcal Conjugate Vaccine Administered in a 2+1 Schedule to Healthy Infants in The Gambia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Serum Institute of India Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council Unit, The Gambia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>FHI 360</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current Phase 3 descriptive study will provide data necessary to evaluate the safety and
      immunogenicity of PNEUMOSIL when administered in an alternative schedule to the 3 dose
      primary schedule (3+0) evaluated in the Phase 3 pivotal trial (VAC-056) - namely in a 2 dose
      primary and booster (2+1) schedule - and compare immunogenicity to that of both currently
      licensed second-generation PCVs administered in the same 2+1 schedule.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective, single center, randomized, active-controlled, observer-blind, Phase 3
      descriptive study, 660 healthy Gambian pneumococcal conjugate vaccine (PCV)-naïve infants
      will be randomized 1:1:1 to receive 3 doses of either PNEUMOSIL, Synflorix or Prevenar 13 at
      6 weeks, 14 weeks and 9 months of age. Standard EPI vaccinations in The Gambia, will be given
      concomitantly with all 3 doses of study vaccine.Blood will be collected 4 weeks post second
      dose, pre-booster and 4 weeks post booster dose for immunogenicity assessments.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 18, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>4 weeks post booster dose</time_frame>
    <description>Serotype-specific serum IgG GMCs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Solicited local and systemic adverse events</measure>
    <time_frame>Day 0-Day 6 post vaccination</time_frame>
    <description>Number and severity of solicited local and systemic adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unsolicited AEs and serious adverse events</measure>
    <time_frame>Approximately from age of 6 weeks through 4 weeks post booster dose</time_frame>
    <description>Number, severity and relatedness of all unsolicited AEs and serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-booster OPA GMTs</measure>
    <time_frame>4 weeks post booster dose</time_frame>
    <description>Serotype-specific serum OPA GMTs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-booster seroresponse rates</measure>
    <time_frame>4 weeks post booster dose</time_frame>
    <description>Percentage of subjects with serotype-specific serum IgG concentrations ≥ 0.35 μg/mL, with serotype-specific serum IgG concentrations ≥ 1.0 µg/mL and with serotype-specific serum OPA titers ≥ 1:8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-primary IgG responses</measure>
    <time_frame>4 weeks post completion of primary vaccination</time_frame>
    <description>Percentage of subjects with serotype-specific serum IgG concentrations ≥ 0.35 μg/mL and Serotype-specific serum IgG GMCs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-primary OPA responses</measure>
    <time_frame>4 weeks post completion of primary vaccination</time_frame>
    <description>Percentage of subjects with serotype-specific serum OPA titers ≥ 1:8 and Serotype-specific serum OPA GMTs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of post-primary IgG responses</measure>
    <time_frame>Approximately 9 months of age</time_frame>
    <description>Percentage of subjects with serotype-specific serum IgG concentrations ≥ 0.35 μg/mL and Serotype-specific serum IgG GMCs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of post-primary OPA responses</measure>
    <time_frame>Approximately 9 months of age</time_frame>
    <description>Percentage of subjects with serotype-specific OPA titers ≥ 1:8 and Serotype-specific serum OPA GMTs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Booster Effects</measure>
    <time_frame>4 weeks post booster comparison to 4 weeks post primary vaccination</time_frame>
    <description>Ratio of serotype-specific serum IgG GMCs measured 4 weeks post booster dose to serotype-specific IgG GMCs measured 4 weeks post completion of primary vaccination and Ratio of serotype-specific serum OPA GMTs measured 4 weeks post booster dose to serotype-specific serum OPA GMTs measured 4 weeks post completion of primary vaccination</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">660</enrollment>
  <condition>Pneumonia, Pneumococcal</condition>
  <arm_group>
    <arm_group_label>Pneumosil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PCV-10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevenar 13</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PCV-13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synflorix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PCV-10</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumosil</intervention_name>
    <description>One single dose contains 2μg of polysaccharide for serotypes 1, 5, 6A, 7F, 9V, 14, 19A, 19F and 23F, and 4μg for serotype 6B formulated with aluminium phosphate as an adjuvant in an appropriate buffer</description>
    <arm_group_label>Pneumosil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar 13</intervention_name>
    <description>One single dose contains 2.2 µg of the following pneumococcal polysaccharides serotypes - 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F - and 4.4 µg of pneumococcal polysaccharide serotype 6B, all conjugated to CRM197 and absorbed onto aluminum phosphate</description>
    <arm_group_label>Prevenar 13</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Synflorix</intervention_name>
    <description>One single dose contains 1μg of polysaccharide for serotypes 1, 5, 6B, 7F, 9V, 14, and 23F, and 3μg of serotypes 4, 18C, and 19F formulated with aluminum phosphate as an adjuvant.</description>
    <arm_group_label>Synflorix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  They are healthy infants based on medical history and clinical assessment.

          -  They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.

          -  Subject's parent must provide voluntary written/thumb-printed informed consent and be
             willing to comply with study requirements and procedures.

          -  Subjects must have been born full-term, have a weight-to-height Z score of ≥ -2 at the
             time of enrollment (WHO child growth standard), and be ≥ 3.5 kg at randomization.

          -  Subject's parents must be available for the duration of trial participation

        Exclusion Criteria:

          -  Use of any investigational medicinal product prior to randomization.

          -  Previous vaccination against or infection with S. pneumoniae.

          -  History of anaphylactic shock or an allergic reaction to any prior vaccination.

          -  Any fever, illness (including malaria).

          -  Receipt of another study vaccine within 30 days of study start.

          -  Chronic administration of an immunosuppressant or administration of immunoglobulins

          -  History of blood disorder, primary immunodeficiency, or a sibling who has such a
             diagnosis or who died suddenly without apparent cause.

          -  History of meningitis, seizures or any neurological disorder.

          -  Exposure to HIV by history.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>56 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ed Clarke, MB ChB, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MRCG at LSHTM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MRCG at LSHTM</name>
      <address>
        <city>Banjul</city>
        <state>West Africa</state>
        <country>Gambia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Gambia</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 22, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Pneumococcal</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

